Mancuso Michelangelo, La Morgia Chiara, Valentino Maria Lucia, Ardissone Anna, Lamperti Costanza, Procopio Elena, Garone Caterina, Siciliano Gabriele, Musumeci Olimpia, Toscano Antonio, Primiano Guido, Servidei Serenella, Carelli Valerio
Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Italy.
IRCCS Istituto Delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy.
Mitochondrion. 2021 May;58:243-245. doi: 10.1016/j.mito.2021.03.011. Epub 2021 Mar 30.
Patients with mitochondrial diseases, who usually manifest a multisystem disease, are considered potentially at-risk for a severe coronavirus disease 2019 (COVID-19). The objective of this study is to analyze the clinical features, prognosis and outcomes of COVID-19 in patients with primary mitochondrial diseases in a cohort of patients followed in Italy. We searched for patients with primary mitochondrial diseases and COVID-19 followed by the Italian Collaborative Network of Mitochondrial Diseases. In a total of 1843 patients followed by the National Network, we have identified from March 1st to January 30th, 2021, 27 SARS-CoV-2 infection. Most of the patients were pauci or asymptomatic (85%) and treated at home. The most common signs of COVID-19 were fever (78,9%), fatigue (47,4%), myalgia (42,1%), cough and headache (36,8%), and dyspnea (31,6%). Those who required COVID-19 therapy were treated with low-molecular-weight heparin, glucocorticoids, and antibiotics (mainly azithromycin) without serious side effects related to the therapy. Five patients (18,5%) clinically deteriorated during the infection, and one of them died for pneumonia. Primary mitochondrial diseases infected individuals seemed to be similarly affected by SARS-CoV-2 compared with the general Italian population in terms of clinical presentation and outcome.
线粒体疾病患者通常表现为多系统疾病，被认为有患重症2019冠状病毒病（COVID-19）的潜在风险。本研究的目的是分析意大利一组接受随访的原发性线粒体疾病患者中COVID-19的临床特征、预后和转归。我们在意大利线粒体疾病协作网络随访的患者中寻找原发性线粒体疾病合并COVID-19的患者。在国家网络随访的总共1843名患者中，我们在2021年3月1日至1月30日期间确定了27例SARS-CoV-2感染病例。大多数患者症状轻微或无症状（85%），在家接受治疗。COVID-19最常见的症状是发热（78.9%）、疲劳（47.4%）、肌痛（42.1%）、咳嗽和头痛（36.8%）以及呼吸困难（31.6%）。那些需要COVID-19治疗的患者接受了低分子量肝素、糖皮质激素和抗生素（主要是阿奇霉素）治疗，未出现与治疗相关的严重副作用。5名患者（18.5%）在感染期间临床病情恶化，其中1人死于肺炎。原发性线粒体疾病感染者在临床表现和转归方面似乎与意大利普通人群受SARS-CoV-2的影响相似。
